Mutation patterns in the RT region of hepatitis B virus P gene in patients treated with nucleoside/nucleotide analogs.
- Author:
Jun DENG
1
;
Dong-hua ZHANG
;
De-min YU
;
Li CHEN
;
Xin-xin ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Antiviral Agents; pharmacology; therapeutic use; DNA Mutational Analysis; DNA, Viral; genetics; Drug Resistance, Viral; Female; Gene Products, pol; genetics; Genes, Viral; Genetic Variation; Hepatitis B virus; drug effects; genetics; Hepatitis B, Chronic; drug therapy; genetics; virology; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; pharmacology; therapeutic use; Reverse Transcriptase Polymerase Chain Reaction; methods; Young Adult
- From: Chinese Journal of Hepatology 2009;17(5):342-345
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze mutation patterns in the RT region of hepatitis B virus (HBV) P gene in patients treated with nucleoside or nucleotide analogs.
METHODSViral DNA was extracted from 227 serum samples of chronic hepatitis B patients from September, 2005 to March, 2007. The RT region of HBV P gene was PCR-amplified and sequenced.
RESULTSKnown resistant mutations were found in 111 cases (48.9%) among 227 samples, 75 cases with clear therapy history. Novel mutations, including A222T, L229V and S256C, were also found. The incidence of multi-drug resistance in patients sequentially treated with lamivudine and adefovir was 25% (4/16), and none of the patients treated with lamivudine plus adefovir in combination shown multi-drug resistance.
CONCLUSIONThe patterns of mutation is complex in nucleotide analogue treated patients. Switching to adefovir in lamivudine resistant patients may lead to multi-drug resistance. Novel mutations identified in this study need further investigation.
